

#6

T02780" 5525680




FIG.1A

F02780 "66952860




FIG. 1B





FIG.1C

10/27/2009 5:55:25 PM




**FIG.2A**

**FIG.2B**

**FIG.2C**

FIG. 2D



FOOT 20° 66.95E 26.0




FIG. 3




FIG. 4




FIG. 6




FIG. 5




FIG. 7

Group <sup>a</sup>	Survivors/ Total (%)	Mean Day to Death	Paralyzed/ Total (%)	Vaginal Virus Titer <sup>b</sup>		
				Day 2 <sup>c</sup>	Day 4	Day 6
Vaccine, 10 µg	8/10 (80)	12.5 ± 0.7	5/10 (50)	3.8 ± 1.9	2.3 ± 1.2	<1.5 ± 0.0
Vaccine, 100 µg	10/10 (100) <sup>†</sup>	>21	0/10 (0)*	3.0 ± 1.30	2.0 ± 0.7†	<1.5 ± 0.0
Placebo	6/10 (60)	14.8 ± 4.0	8/10 (80)	5.0 ± 2.3	3.1 ± 1.4	1.6 ± 0.3

a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

b Log10 cell culture infections doses per ml, determined from vaginal swabs.

c After virus inoculation.

\* P<0.001.

† P=0.08, & P=0.06.

FIG. 8

192780-6635E360






FIG. 9






FIG.11




FIG.12




FIG.13A




FIG.13B




FIG.14A




FIG.14B




FIG.15A




FIG.15B